Sanofi (SAN) Given a €72.00 Price Target at Jefferies Group

Jefferies Group set a €72.00 ($88.89) price objective on Sanofi (EPA:SAN) in a research note published on Friday morning. The firm currently has a neutral rating on the stock.

Several other equities research analysts also recently commented on the stock. Berenberg Bank set a €83.00 ($102.47) price objective on shares of Sanofi and gave the stock a neutral rating in a research note on Monday, April 9th. Morgan Stanley set a €66.00 ($81.48) price objective on shares of Sanofi and gave the stock a sell rating in a research note on Wednesday, March 28th. Deutsche Bank set a €88.00 ($108.64) price objective on shares of Sanofi and gave the stock a buy rating in a research note on Wednesday, March 28th. Goldman Sachs set a €74.00 ($91.36) price objective on shares of Sanofi and gave the stock a neutral rating in a research note on Tuesday, March 13th. Finally, Kepler Capital Markets set a €84.00 ($103.70) price objective on shares of Sanofi and gave the stock a buy rating in a research note on Monday, March 12th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of €79.41 ($98.04).

How to Become a New Pot Stock Millionaire

EPA:SAN opened at €66.17 ($81.69) on Friday. Sanofi has a 12 month low of €63.09 ($77.89) and a 12 month high of €92.97 ($114.78).

TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/17/sanofi-san-given-a-72-00-price-target-at-jefferies-group.html.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply